NY-IFF
13.12.2021 22:17:13 CET | Business Wire | Press release
IFF (NYSE:IFF) today announced its environmental, social and governance (ESG) roadmap for the combined Company. The 2030 ‘Do More Good Plan’ (the Plan) includes ambitious targets that are aligned with IFF’s purpose of applying science and creativity for a better world.
“With our Do More Good Plan, we are taking another bold step in our aspirations to do more for people, planet and product,” said Andreas Fibig, IFF Chairman & CEO. “Ten years ago, when we formalized our sustainability program, we knew the journey would lead us to being even better partners with our customers, communities and stakeholders. To date, our efforts have achieved ratings above industry standards and have had real impact throughout our value chain. Today, we are going further. With this Plan, we are embedding even more ambitious targets, in our operations and partnerships, to address the urgent issues that affect our world.”
The Plan comprises four key areas:
1. Environmental
To support environmental stewardship across its operations, IFF will accelerate its commitment to climate action by setting new science-based ambitions to reduce greenhouse gas emissions (GHGs) by 50% below 2021 levels by 2030; to achieve net zero GHGs by 2040; and to be net positive by 2050.1 By 2030, IFF will also verify zero waste to landfill, including plastics minimization, for all major manufacturing facilities, and champion water stewardship solutions within its operations. Additionally, the Company commits to accelerating its responsible sourcing practices by promoting regenerative ecosystems and achieving zero deforestation for strategic raw material supply chains by 2030, beginning with palm, soy and wood.
2. Social
Aligned with its social responsibility targets, IFF is advancing its commitment to people and communities. Milestones include strengthening diversity, equity & inclusion within its workforce by having 40% people of color in management roles in the United States by 2030, with equitable representation in other markets globally; and aiming for greater gender balance with women holding 50% of all management roles, companywide. IFF is also committed to continuously improving its safety program by striving for an injury-free workplace, and achieving world-class safety performance. Within its responsible sourcing program, the Company will continue to promote human rights and animal welfare, while supporting farmers’ livelihoods and ensuring prosperous and equitable value chains.
3. Governance
To enhance accountability in line with evolving stakeholder expectations, the Company will launch ESG metrics tied to executive compensation and will expand oversight for ESG at the Board of Directors level. IFF remains on track to increase its transparency in disclosures and key performance indicators.
4. Sustainable Solutions
IFF will assist its customers in achieving their own ESG goals by delivering an expanded suite of sustainable solutions for the market. With this focus on sustainable growth, IFF intends for all new innovations to have a sustainability value proposition that supports people and planet with health & wellbeing products, solutions for sustainable food systems and circular economy strategies. As one of its climate action aspirations, the Company aims to enable customers and consumers to save at least 50 times more CO2 e than generated at IFF’s own manufacturing sites by providing innovation solutions such as sustainable proteins as well as enzymes solutions which enable food waste reduction and energy savings.
“Our purpose is inextricably tied to securing a better, more sustainable world,” said Dr. Greg Yep, EVP, Chief Research & Development, Global Integrated Solutions and Sustainability Officer. “This Plan is designed to build on our long-standing commitments to people and planet while showcasing our strengths in science, technology and innovation. As a next step, we are operationalizing these ambitions and their action plans across our divisions and functions so that, together, we will achieve our goals and hold ourselves accountable in meaningful and measurable ways.”
Today’s announcement builds on IFF’s track record of ESG accomplishments, including the following:
2021
- CDP “A” list designation for climate change, water security and forests.
- Dow Jones Sustainability Indices placement, 2nd consecutive year.
- Best Place to Work for LGBTQ Equality award, 3rd consecutive year.
- Best Place to Work for Disability Inclusion award, 2nd consecutive year.
2020
- Economic Dividend for Gender Equality (EDGE) recognition for being the first company to earn Move level certification, globally.
To learn more about IFF’s Do More Good Plan, please visit iff.com/responsibilities/strategy-reporting and refer to IFF’s forthcoming 2021 sustainability report.
Welcome to IFF
At IFF (NYSE: IFF), an industry leader in food, beverage, scent, health and biosciences, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com , Twitter , Facebook , Instagram , and LinkedIn .
_____________________________________
1
Pending finalization and approval by the Science Based Targets Initiative
View source version on businesswire.com: https://www.businesswire.com/news/home/20211213005605/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
